Medicine
Optiray 350 111150 mg/150 mL injection
Optiray 350 111150 mg/150 mL injection is a prescription medicine containing Ioversol for intra-arterial, intravenous use, marketed by Liebel-Flarsheim, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F). Store…
Key facts
- Active ingredient (INN)
- Ioversol
- Brand
- Optiray 350
- Strength
- 111150 mg/150 mL
- Dosage form
- Injection
- Route
- Intra-arterial, intravenous
- Packs
- 12 bottles of 150 mL
- Marketing authorisation holder
- Liebel-Flarsheim
- Manufacturer
- Liebel-Flarsheim
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F). Store up to 40°C (104°F) for up to one month in a contrast media warmer utilizing circulating warm air. Protect from strong daylight or direct exposure to the sun. May store OPTIRAY for periods longer than one month. Store OPTIRAY RFID-tagged syringes at the same conditions listed for the drug product.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V08AB07 Ioversol
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 4 March 2012
- Identifiers
- DailyMed set ID 549d38db-d4ed-4708-8f76-7cdaa157063fNDC 0019-1333Application NDA019710
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 12 bottle, glass in 1 carton / 150 mL in 1 bottle, glass | 0019-1333-16 | Liebel-Flarsheim | 4 March 2012 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 30 December 1988 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Ioversol
Clinical summary
Ioversol is a radiographic contrast agent indicated for oPTIRAY is a radiographic contrast agent indicated for the following, among other approved uses. It is available as injection for intra-arterial and intravenous use. MedsAcross supplies Ioversol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about IoversolFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Optiray 320 prescribing information (Liebel-Flarsheim) · U.S. National Library of Medicine, DailyMed
Need Optiray 350 111150 mg/150 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.